Peloton Therapeutics, Inc. is an oncology drug discovery and development company focused on advancing first-in-class small molecule therapies that provide patients suffering from life-threatening diseases with new therapeutic options.

The company is driving forward multiple oncology programs targeting unexploited molecular vulnerabilities including adaptive processes that are induced in the tumor microenvironment by hypoxia, nutrient stress, and that result in evasion of anti-tumor immune responses.

Peloton Therapeutics, Inc. Presents Promising Data on First Inhibitor of HIF-2α for Renal Cell Carcinoma at 2015 AACR Annual Meeting

  • Preclinical data indicates that lead investigational compound PT2385 suppresses gene expression essential for tumor growth, proliferation, and angiogenesis
  • Phase 1 study of PT2385 ongoing; first clinical stage HIF-2α program

Link to Article